title: DNA replication stress response involving PLK1, CDC6, POLQ, RAD51 and CLASPIN upregulation prognoses the outcome of early/mid-stage non-small cell lung cancer patients.
abstract: Lung cancer is the leading cause of cancer deaths worldwide. Clinical staging classification is generally insufficient to provide a reliable prognosis, particularly for early stages. In addition, prognostic factors are therefore needed to better forecast life expectancy and optimize adjuvant therapeutic strategy. Recent evidence indicates that alterations of the DNA replication program contribute to neoplasia from its early stages and that cancer cells are frequently exposed to endogenous replication stress. We therefore hypothesized that genes involved in the replication stress response may represent an under-explored source of biomarkers. Expressions of 77 DNA replication-associated genes implicated in different aspects of chromosomal DNA replication, including licensing, firing of origins, elongation, replication fork maintenance and recovery, lesion bypass and post-replicative repair were determined in primary tumors and adjacent normal tissues from 93 patients suffering from early- or mid-stage non-small cell lung cancer (NSCLC). We then investigated a statistically significant interaction between gene expressions and survival of early-stage NSCLC patients.The expression of five genes, that is, POLQ, PLK1, RAD51, CLASPIN and CDC6 was associated with overall, disease-free and relapse-free survival. The expression levels are independent of treatment and stage classification. Except RAD51, their prognostic role on survival persists after adjustment on age, sex, treatment, stage classification and conventional proliferation markers, with a hazard ratio of 36.3 for POLQ (95%CI 2.6-517.4, P=0.008), 23.5 for PLK1 (95%CI 1.9-288.4, P=0.01), 20.7 for CLASPIN (95%CI 1.5-275.9, P=0.02) and 18.5 for CDC6 (95%CI 1.3-267.4, P=0.03). We also show that a five-gene signature including POLQ, PLK1, RAD51, CLASPIN and CDC6 separates patients into low- and high-risk groups, with a hazard ratio of 14.3 (95% CI 5.1-40.3, P<0.001). This 'replication stress' metamarker may be a reliable predictor of survival for NSCLC, and may also help understand the molecular mechanisms underlying tumor progression.
authors.affiliation: 1] Cancer Research Center of Toulouse, Inserm U1037, CNRS ERL5294, University of Toulouse, University Paul Sabatier, Toulouse, France [2] Rangueil-Larrey University Hospital, University of Toulouse, University Paul Sabatier, Toulouse, France.
authors.forename: C
authors.initials: C
authors.lastname: Allera-Moreau
authors.forename: I
authors.initials: I
authors.lastname: Rouquette
authors.forename: B
authors.initials: B
authors.lastname: Lepage
authors.forename: N
authors.initials: N
authors.lastname: Oumouhou
authors.forename: M
authors.initials: M
authors.lastname: Walschaerts
authors.forename: E
authors.initials: E
authors.lastname: Leconte
authors.forename: V
authors.initials: V
authors.lastname: Schilling
authors.forename: K
authors.initials: K
authors.lastname: Gordien
authors.forename: L
authors.initials: L
authors.lastname: Brouchet
authors.forename: M B
authors.initials: MB
authors.lastname: Delisle
authors.forename: J
authors.initials: J
authors.lastname: Mazieres
authors.forename: J S
authors.initials: JS
authors.lastname: Hoffmann
authors.forename: P
authors.initials: P
authors.lastname: Pasero
authors.forename: C
authors.initials: C
authors.lastname: Cazaux
references.citation: Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):8956-61
references.pmid: 18579778
references.citation: J Exp Med. 2012 Mar 12;209(3):455-61
references.pmid: 22370720
references.citation: J Natl Cancer Inst. 1995 Aug 2;87(15):1114-25
references.pmid: 7674315
references.citation: Curr Opin Genet Dev. 1998 Feb;8(1):14-20
references.pmid: 9529600
references.citation: Cancer Res. 1995 Jan 15;55(2):220-3
references.pmid: 7812947
references.citation: J Natl Cancer Inst. 2011 Dec 21;103(24):1859-70
references.pmid: 22157961
references.citation: Genes Dev. 2007 Dec 15;21(24):3331-41
references.pmid: 18079179
references.citation: Oncogene. 2010 Feb 11;29(6):876-87
references.pmid: 19901968
references.citation: Mol Cell Biol. 2007 Nov;27(21):7669-82
references.pmid: 17785453
references.citation: DNA Repair (Amst). 2008 Jan 1;7(1):119-27
references.pmid: 17920341
references.citation: Science. 1994 Dec 23;266(5193):1954-6
references.pmid: 7801120
references.citation: Mol Cell Biol. 2009 Jun;29(12):3344-54
references.pmid: 19380493
references.citation: Cell. 2005 Feb 11;120(3):315-28
references.pmid: 15707891
references.citation: Curr Opin Cell Biol. 2003 Apr;15(2):232-40
references.pmid: 12648680
references.citation: Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13390-5
references.pmid: 20624954
references.citation: Nat Genet. 2007 Jan;39(1):93-8
references.pmid: 17143284
references.citation: Cell Cycle. 2003 May-Jun;2(3):194-5
references.pmid: 12734423
references.citation: Nat Med. 2008 Aug;14(8):822-7
references.pmid: 18641660
references.citation: Lancet. 2012 Mar 3;379(9818):823-32
references.pmid: 22285053
references.citation: Oncogene. 2002 Feb 14;21(8):1150-8
references.pmid: 11850834
references.citation: Hum Mol Genet. 2005 Oct 15;14 Spec No. 2:R197-205
references.pmid: 16244318
references.citation: DNA Repair (Amst). 2011 Oct 10;10(10):1060-5
references.pmid: 21900052
references.citation: Cancer Res. 2011 Sep 1;71(17):5621-5
references.pmid: 21775519
references.citation: Nat Rev Mol Cell Biol. 2004 Jun;5(6):429-40
references.pmid: 15173822
references.citation: J Pathol. 2007 Feb;211(3):331-9
references.pmid: 17152083
references.citation: Nature. 2005 Apr 14;434(7035):864-70
references.pmid: 15829956
references.citation: Mol Oncol. 2011 Aug;5(4):368-73
references.pmid: 21820372
references.citation: EMBO J. 2004 Nov 10;23(22):4484-94
references.pmid: 15496986
references.citation: Nucleic Acids Res. 2007;35(11):3551-60
references.pmid: 17483519
references.citation: Science. 2008 Mar 7;319(5868):1352-5
references.pmid: 18323444
references.citation: N Engl J Med. 2007 Feb 22;356(8):800-8
references.pmid: 17314339
references.citation: Nature. 1996 Jan 11;379(6561):183-6
references.pmid: 8538772
references.citation: J Natl Cancer Inst. 2010 Apr 7;102(7):464-74
references.pmid: 20233996
references.citation: Oncogene. 2006 Jul 6;25(29):4027-32
references.pmid: 16518415
references.citation: Nature. 2006 Nov 30;444(7119):633-7
references.pmid: 17136093
references.citation: Nature. 1999 Jun 17;399(6737):700-4
references.pmid: 10385124
references.citation: Am J Pathol. 2004 Oct;165(4):1351-65
references.pmid: 15466399
references.citation: Nat Rev Cancer. 2005 Feb;5(2):135-41
references.pmid: 15660109
references.citation: Mol Cell. 2012 Feb 10;45(3):371-83
references.pmid: 22325354
references.citation: Nucleic Acids Res. 2010 Apr;38(7):2314-31
references.pmid: 20064876
references.citation: Cancer Cell. 2003 Feb;3(2):105-10
references.pmid: 12620405
references.citation: Hum Pathol. 1997 Feb;28(2):233-7
references.pmid: 9023408
references.citation: Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1692-7
references.pmid: 18234858
references.citation: Clin Cancer Res. 2010 Feb 15;16(4):1206-15
references.pmid: 20145178
references.citation: J Clin Oncol. 2010 Oct 10;28(29):4417-24
references.pmid: 20823422
references.citation: Mol Cell. 2000 Oct;6(4):839-49
references.pmid: 11090622
references.citation: Nature. 2005 Apr 14;434(7035):907-13
references.pmid: 15829965
references.citation: Mol Cell Biol. 2011 Dec;31(23):4844-56
references.pmid: 21947279
references.citation: Cell. 2010 Apr 16;141(2):243-54
references.pmid: 20362325